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Purpose: The dopamine (DA) system in the retina is critical to normal visual development as lack of retinal DA signaling
may contribute to myopic development. The involvement of DA in myopic development is complex and may be different
between form deprivation and hyperopic defocus. This study evaluated effects of a non-selective DA receptor agonist,
apomorphine (APO) on refractive development in guinea pigs treated with form deprivation or hyperopic defocus.
Methods: APO was subconjunctivally injected daily for 11 days in form-deprived (0.025 to 2.5 ng/µl) and defocused
(0.025 to 250 ng/µl) eyes. Changes in ocular biometry and retinal concentration of DA and its metabolites (DOPAC) were
measured in the 2 animal models to assess the level of DA involvement in each of the models (the less the change, the
lower the involvement).
Results: Similar myopic degree was induced in both the deprived and defocused eyes (−4.06 D versus −3.64 D) at 11
days of the experiment. DA and DOPAC levels were reduced in the deprived eyes but did not change significantly in the
defocused eyes compared to the fellow and normal control eyes. A subconjunctival injection of APO daily for 11 days at
concentrations ranged from 0.025 to 2.5 ng/µl inhibited form deprivation myopia in a concentration-dependent manner.
By contrast, the APO treatment ranged from 0.025 to 250 ng/µl did not effectively inhibit the defocus-induced myopia
and the associated axial elongation.
Conclusions: DA signaling may play a more critical role in form deprivation myopia than in defocus-induced myopia,
raising a question whether the mechanisms of DA signaling are different under these two types of experimental myopia.
Dopamine (DA) signaling in the retina is believed to be
critical  during  the  development  of  experimental  myopia
[1-6]. Retinal DA is released exclusively from amacrine or
interplexiform cells and its release increases during daytime
or illumination but declines in darkness [7,8]. Myopia can be
induced  experimentally  either  by  form  deprivation  or
hyperopic  defocus  of  the  retinal  image.  These  2  visual
manipulations cause axial elongation and choroid thinning of
the eye, resulting in axial myopia [2,9,10]. Similar changes in
gene and protein expression of some growth factors, such as
egr-1 (early growth response protein 1; ZENK), glucagon,
transforming growth factor (TGF) and crystallins also occur
in the retina of the eyes treated with either form deprivation
or  hyperopic  defocus  [11-15].  Furthermore,  the  refractive
development in these 2 models can be similarly modified by
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controlling the axial lengthening of the eye with dopaminergic
agonists  and  muscarinic  acetylcholine  receptor  (mAChR)
antagonists  [5,16,17],  suggesting  that  both  the  DA  and
cholinergic systems are involved in refractive development of
the eye.
Some  mAChR  antagonists  including  atropine  and
pirenzepine  have  been  used  to  prevent  or  inhibit  the
development  of  myopia  for  decades  in  both  clinical  and
experimental  settings  [17,19-24].  However,  the  long-term
effect of mAChR antagonists on inhibition of myopia is not
fully determined [25,26] and side-effects caused by mAChR
antagonists are unacceptable for some patients. Therefore,
these  agents  are  not  ideal  as  long-term  medications  for
prevention of myopic development [23,25]. DA appears to
function similarly to mAChR antagonists in biologic control
of experimental myopia [11,16,18,27,28]. DA and its agonists
have been used routinely to treat Parkinson disease [29] and
therefore would be acceptable clinically if they were proved
to be effective in the treatment of myopia.
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2824Activation  of  DA  receptors  by  local  administration
(intravitreal,  subconjunctival  or  topical)  of  dopamine,
levodopa (a precursor of dopamine) or apomorphine (APO, a
non-selective  DA  receptor  agonist)  can  inhibit  form
deprivation myopia (FDM) in guinea pigs, rabbits and rhesus
monkeys  [5,28,30,31],  while  APO  and  quipirole  (a  D2
receptor agonist) inhibit both form deprivation and defocus-
induced myopia in chickens [16,32]. Biometric changes in
these myopic eyes mainly manifest as axial elongation of the
eye  and  transient  thinning  of  the  choroid  [5,16,32-37].
However, chicken eyes frequently exposed to flickering (a
dopamine  synthesis  stimulator  as  shown  by  Umino  et  al.
[38] and Dong & McReynolds [39]) do not develop form
deprivation- or defocus-induced myopia [1,40]. Furthermore,
D2 receptor antagonist, sulpiride can enhance FDM [41] and
another D2 antagonist spiperone used together with APO can
compromise the role of APO in inhibition of FDM [42]. These
results  indicate  that  retinal  DA  receptors  are  involved  in
dopaminergic  control  of  ocular  axial  growth  and  the
availability/or  susceptibility  of  the  DA  receptors  plays  a
crucial role in this dopaminergic effect. In contrast, depletion
of  retinal  DA  by  6-hydroxydopamine  (6-OHDA,  a
neurotoxin)  or  reserpine  inhibits  both  FDM  and  defocus-
induced myopia in chickens [27,41,43,44]. As a neurotoxin,
6-OHDA may not only deplete the retinal DA but also damage
other retinal cells and tissues, resulting in a non-dopamine
specific  retardation  of  the  eye  growth.  Therefore,  these
seemingly  paradoxical  results  with  both  activation  and
inactivation of DA signaling should be taken into account with
the toxicity and specificity of the pharmacological agents
used.
Although both FDM and defocus-induced myopia share
some similarities in genetics, proteins and neurobiological
activities, the level of involvement and biologic responses of
the  ocular-neurologic  system  appear  different  in  these  2
models [17,45,46]. For instance, the levels of DA and its major
metabolite, 3, 4-dihydroxyphenylacetic acid (DOPAC) are
reduced in the retina of chickens and monkeys following form
deprivation [27,47]. This is consistent with a decreased rate
of retinal DA release in FDM [43] and the rapid recovery of
retinal DA and DOPAC levels in the chicken eyes recovering
from FDM [48]. On the other hand, reported levels of retinal
DA during defocus-induced myopia are inconsistent in the
literatures [41,49], possibly due to the difference in power of
the negative lenses used. This hypothesis is evidenced with an
increased sensitivity of the eye to the suppressive effect of
APO  on  defocus-induced  myopia  when  the  negative-lens
power is increased [10,41]. A more recent study shows that
APO is more effective in control of defocus-induced myopia
than in FDM in 8-day old chickens [16]. Atropine has a greater
inhibitory effect than the combination of atropine and APO
on FDM, but this is not the case for defocus-induced myopia
[16]. Constant lighting, which breaks the diurnal cycle of DA
levels  in  the  retina  can  inhibit  FDM,  but  does  not  affect
development of defocus-induced myopia [50]. Finally, the
growth of sclera in response to the negative lens wear is much
more rapid than that to form deprivation [46]. All of these
results  indicate  that  mechanisms  mediated  by  the
dopaminergic system in control of axial growth of the eye are
not exactly the same between form deprivation and hyperopic
defocus in chicken models.
An understanding of DA involved in the development of
myopia  could  help  select  potential  medical  treatment  for
refractive  errors.  At  present,  neurochemical  mechanisms
involved in myopia development have not been studied as
extensively in mammals as in chickens although studies on
monkeys and tree shrews have provided some results similar
to those in chickens [51,52]. Guinea pigs are a promising
alternative to chickens and other mammals for the study of
experimental myopia [34,53-56]. They develop myopia more
rapidly compared to monkeys [57-59] and have shown that
local DA signaling plays a significant role in inhibition of
form deprivation myopia [5,6,60].
In this study, we aimed to explore the possible different
roles of DA signaling between the FDM and defocus-induced
myopia  using  guinea  pigs.  Specifically,  we  investigated
effects of FDM and defocus-induced myopia on retinal DA
concentration and the associated metabolism. Furthermore,
we determined the effect of local administration of the non-
selective DA agonist APO on refraction and the associated
biometric changes in FDM and defocus-induced myopia. A
potency curve of different doses of APO used for guinea pigs
was also established as compared to that from the chicken
models.
METHODS
Experimental design: The animal research in this study was
approved  by  the  Animal  Care  and  Ethics  Committee  at
Wenzhou Medical College (Wenzhou, China). Treatment and
care  of  animals  were  conducted  according  to  the  ARVO
Statement for the Use of Animals in Ophthalmic and Vision
Research. One hundred and forty pigmented guinea pigs at
age of 3 weeks were randomly assigned to FDM (a facemask
worn monocularly) or defocus-induced myopia (a -4.00 D
[diopter] lens worn monocularly) and control groups. The
FDM groups were treated with 0.025 ng/µl APO (n=8), 0.25
ng/µl APO (n=7), 2.5 ng/µl APO (n=6), vehicle (0.1 mg/ml
ascorbic acid, n=9), or FDM-only (n=6). The defocus-induced
myopia groups were treated with 0.025 ng/µl APO (n=12),
0.25 ng/µl APO (n=13), 2.5 ng/µl APO (n=14), 25 ng/µl APO
(n=8), 250 ng/µl APO (n=8), vehicle (0.1 mg/ml ascorbic acid,
n=14),  or  defocus-only  (n=17).  The  control  groups  were
treated with 2.5 ng/µl APO (n=6), vehicle (0.1 mg/ml ascorbic
acid, n=6), or no treatment (n=6). APO dissolved in 100 μl
vehicle (or vehicle alone) was administered monocularly by
subconjunctival injection into eyes of the designated groups.
Ocular biometric parameters were measured in both eyes of
individual animals before and at 11 days of treatment.
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2825Establishment  of  axial  myopia  by  form  deprivation  and
hyperopic defocus: FDM was achieved using a latex shield to
cover one eye, as described previously [54]. For defocus-
induced myopia, a latex-made facemask was held in place by
a rubber-band around the head of animals, leaving both eyes,
the nose, mouth and ears freely exposed. A - 4.00 D lens
(Boston IV, diameter: 11.8 mm, optical zone: 11.0 mm, base
curve: 12.0 mm; Xinshijie, Wenzhou, China) was glued onto
a plastic lens frame. The lens frame was then attached to the
facemask around one eye by a fabric hook-and-loop fastener
(Velcro; Hongxin, Shenzhen, China) after the optical center
of the lens was aligned with the pupil center. The lens was
detached and cleaned on both sides with a water-wetted gauze
at least once daily followed by re-attachment to the facemask.
All  the  animals  were  maintained  on  a  cycle  of  12-h
illumination  (500  Lux)  and  12-h  darkness  during  the
experimental period.
Pharmacological manipulation: APO (Tocris, Glasgow, UK)
solution  at  different  concentrations  was  freshly  prepared
before each injection. The drug was dissolved in sterilized
injection water with ascorbic acid added (0.1 mg/ml) as an
antioxidant.  The  vehicle  solution  contained  0.1  mg/ml  of
ascorbic acid in sterilized injection water. Only one eye of
each animal received the injection (deprived eyes in FDM
groups; defocused eyes in defocus-induced myopia groups;
randomized  right  or  left  eyes  in  other  groups).  Topical
anesthesia  was  administered  with  1  to  2  drops  of  0.5%
proparacaine  hydrochloride  (Alcon,  Puurs,  Belgium)  after
removal of the facemask or lens. A subconjunctival injection
of 100 μl APO solution with a concentration from 0.025 ng/
µl to 250 ng/µl APO (same volume for vehicle injection) was
performed using a syringe with a 26-gauge needle once daily
(at 9 AM) for 11 days. The injection site was just through the
conjunctival reflection, 4 mm inferior to the lower corneal
margin. The facemask or lens was placed back on the eye
immediately after each injection. The entire injection period
from  removal  to  replacement  of  the  MDF  or  lens  was
approximately 2 min.
Measurements  of  vitreous  APO  concentration  after
subconjunctival injection: To confirm the concentration of
APO in the injected eyes, 45 extra animals (2 eyes of each)
were used to measure the vitreous concentration of APO using
HPLC before (n=2) and at 0.5 (n=6), 1 (n=6), 6 (n=12), 12
(n=14), and 24 (n=15) h after the subconjunctival injection.
The eyes were placed in liquid nitrogen for about 20 s and
hemisected sagittally in an iced box. The vitreous body was
gently harvested using an iced 1.5-ml Eppendorf (EP) tube,
mixed with ascorbic acid (final concentration 1.0 mg/ml) and
centrifuged at 1,250× g at 4 °C for 5 min. The supernatant
(containing APO) was transferred to another EP tube and
stored at −80 °C. All vitreous samples from the same time
point  were  pooled  into  one  collected  sample  which  was
analyzed 3 times to provide the mean value of APO. The
analytical column was packed with a 5 µm Zorbax Eclipse
XDB C18 (Agilent, Santa Clara, CA) at 30 °C with a 5 µm
XDB C18 as a guard column (Agilent). The mobile phase ran
a mixture (30:70, v/v) of methanol and a solution of 12 mmol/
l sodium dihydrogen phosphate plus 1 mmol/l (w/v) EDTA
adjusted to pH 3.00 with orthophosphoric acid at a flow rate
of 1.0 ml/min. Wavelengths of excitation and emission were
276 nm and 460 nm respectively for both APO and boldine
(internal standard, IS). Retention time for APO and IS were
4.4 min and 3.7 min, respectively.
Biometric measurements: Biometric parameters (refraction,
corneal curvature, and axial components of the eye) were
measured by an optometrist with help from an animal care
assistant during the light cycle (daytime) after removal of the
facemask or lens. The optometrist was masked in regard to the
treatment conditions for each animal.
Refraction was measured by retinoscopy after the pupil
was  completely  dilated  by  topical  administration  of  1%
cyclopentolate hydrochloride (Alcon, Fort worth, TX). The
results of retinoscopy were recorded as the mean value of the
horizontal and vertical meridians [54-56]. Corneal curvature
was measured with a keratometer (OM-4; Topcon, Tokyo,
Japan)  modified  by  attachment  of  an  +8  D  lens  onto  the
anterior surface of the keratometer. A group of stainless steel
balls with diameters from 5.5 to 11.0 mm were measured by
the modified keratometer. Three readings were recorded for
each measurement to provide a mean result. The radius of
corneal curvature was then deduced from the readings on the
balls with known radii [54].
A-scan  ultrasonagraph  (Cinescan  A/B,  frequency:
11MHz; Clermont Ferrand, France) was used to measure axial
components of the eye (lens thickness and vitreous length and
axial length). The conducting velocity was 1,723.3 m/s for
measurement  of  the  lens  thickness  and  1,540  m/s  for
measurement of the vitreous length as described previously
[56]. Each of the axial components was calculated as the mean
of 10 repeated measurements.
Measurements of levels of retinal DA and DOPAC:
Sample preparation—Sixty-three extra animals (2 eyes
of  each)  were  used  to  measure  retinal  levels  of  DA  and
DOPAC under normal visual conditions (n=14) and at 11 days
of form deprivation (n=26) or hyperopic defocus (n=23). After
enucleation of the eye, the retina was dissected on an iced dish,
weighed, homogenized in 150 µl of 1M HClO4 with 3, 4-
dihydroxybenzylamine  (DHBA;  Fluka,  Milwaukee,  WI),
centrifugated at 30,000× g for 30 min at 4 °C and finally the
supernatant was collected and stored at −80 °C [7,61].
Chromatographic process—The analytical column was
packed with a 5 µm Diamonsil C18 (4.6 mm×250 mm I.D.;
Dikma, Shanghai, China) at 30 °C with a 5 µm XDB C18 as
a guard column (4.6 mm×12.5 mm I.D.; Agilent). The mobile
phase ran a mixture (83:17, v/v) of methanol and citrate buffer
solution (0.08 M, pH 4.4; citric acid 50 mM,trisodium citrate
30 mM,octane 0.83 mM,EDTA 0.1 Mm) at a flow rate of
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28261.0 ml/min. The volume of analyzed samples for HPLC was
40 µl. Retention times for DA, DOPAC and internal standard
DHBA were 8.4, 10.0, and 11.4 min, respectively. Peaks of
the three agents were separated without any interfering peaks
between them. DA (Sigma, Buchs, Switzerland) and DOPAC
(Aldrich, Buchs, Switzerland) at five different concentrations
(2.5, 5.0, 12.5,5.0,10.0, 25.0, and 100.0 ng/ml) were used to
form a standard curve with DHBA (concentration: 30 ng/ml)
as  an  internal  standard  for  calibration  of  the  drug
concentration.
Immediately  before  analysis,  perchloric  acid  was
removed from the samples by precipitation with potassium
citrate  solution  and  centrifugation.  The  supernatant  was
passed through a 0.22 µm membrane (Millipore, Billerica,
MA) and an aliquot of 40 µl was injected for HPLC analysis.
The DA/DHBA and DOPAC/DHVA peak-area ratios (As/Ai)
were  plotted  against  the  ratio  of  the  corresponding
concentrations (C). The concentrations of DA and DOPAC
were expressed as ng/mg wet-weight retina [7,61].
Statistics:  Biometric  results  were  compared  between
deprived/defocused eyes and their fellow eyes within the same
group using a paired sample t-test, SPSS Version 12.0 (SPSS,
Chicago,  IL).  These  results  were  also  compared  between
different time points in the same group by independent t-test
and  among  different  groups  by  one-way  ANOVA  with
Bonferroni correction, SPSS Version 12.0. Both the intra-
group and inter-group differences were defined as significant
at p<0.05 and highly significant at p<0.01.
RESULTS
Levels  of  retinal  DA  and  DOPAC  in  different  visual
environments: There was no significant difference in levels of
retinal  DA,  DOPAC,  and  DOPAC/DA  between  eyes  of
individual animals in the normal control group (Table 1 and
Figure 1), or between the right eyes of the normal control
group and the fellow eyes in FDM-only and defocus-only
groups. However, the levels of DA, DOPAC and DOPAC/DA
in the deprived eyes were significantly lower than in the fellow
eyes (FDM versus FDM fellow: 0.273 versus 0.292 ng/mg for
DA, 0.114 versus 0.134 ng/mg for DOPCA, 0.424 versus
0.462 ng/mg for DOPAC/DA; p≤0.042, paired sample t-test)
and  the  normal  control  eyes  (FDM  versus  normal:  0.273
versus 0.327 ng/mg for DA, 0.114 versus 0.142 ng/mg for
DOPAC, 0.424 versus 0.438 ng/mg for DOPAC/DA with
p≤0.021 for DA, DOPAC and p>0.05 for DOPAC/DA, one-
way ANOVA). In contrast, the defocus-only group showed
similar levels of DA and its metabolites between eyes of the
individual animals (DA: 0.288 versus 0.309 ng/mg, DOPAC:
0.115 versus 0126 ng/mg, DOPAC/DA: 0.407 versus 0.409
ng/mg;  p>0.064:  defocus  versus  defocus  fellow,  paired
sample  t-test).  However,  the  defocused  eyes  showed  a
significant  reduction  in  retinal  DOPAC  level  but  no
significant  changes  in  DA  or  DOPAC/DA  levels  when
compared to the normal control group (Figure 1).
Intravitreous  concentration  of  APO  after  subconjunctival
injection: A single subconjunctival injection of 100 µg APO
(100 µg in 100 µl: 1 mg/ml) produced a vitreous concentration
of 87.51 ng/ml, 57.77 ng/ml, 21.84 ng/ml and 9.15 ng/ml in
0.5, 1, 6, and 12 h, respectively (Figure 2). The concentration
at the 12-h time point was maintained for at least another 12
h. The total amount of drug in the vitreous chamber after
subconjunctival injection of 100 µg APO was 13.13 ng, 8.67
ng, 3.28 ng, and 1.37 ng at 0.5, 1, 6, and 12 h after drug
injection,  respectively,  based  on  an  estimated  volume  of
0.15 ml for the guinea pig vitreous chamber (guinea pigs’
vitreous chamber length estimated as 0.36 cm, the vitreous
chamber volume calculated according to volume formula:
V=πr3). The amount of APO that reached the vitreous was only
approximately  1/104  of  the  amount  that  was  injected
subconjunctivally. Therefore, a subconjunctival injection of
100 µl of 2.5 ng/µl APO (the concentration and volume used
in the present study) could produce 25 pg APO (4.37 nM) in
the vitreous chamber 0.5 h after the injection with the amount
maintained at approximately 8 pg (1.40 nM) within the first 6
h, followed by a constant amount of 4–5 pg (0.70–0.87 nM)
until the next injection (given that the difference of diffusion
index between different drug concentrations was neglected).
Changes  of  refraction  and  axial  components  in  different
treatment groups:
Baseline  and  normal  control  groups—Prior  to  the
experiment, there was no significant difference between eyes
of individual animals in each group in refraction, corneal
radius of curvature and various axial components (Figure 3
and Figure 4). There was also no significant difference in the
right or left eyes between any two groups for any of the
biometric  results  before  the  experiment  (p>0.05,  one-way
ANOVA). Therefore, only results from the right eyes of the
animals in the normal control group were used for comparison
with the eyes from the other groups.
There was no significant difference between eyes of the
same animals in each of the 3 control groups (normal control,
vehicle-only and 2.5 ng/μl APO-only) in refraction, corneal
radius of curvature and various axial components at day 11 of
the experiment (p≥0.068, paired sample t-test).
FDM groups—There was no significant difference in
any of the biometric results between the fellow eyes of each
FDM group and the normal control eyes at 11 days (p≥0.314,
right eyes in normal control vs fellow eyes in each FDM
group, one-way ANOVA), indicating that the fellow eyes of
all FDM groups can be used as a control to assess biometric
changes in the deprived eyes. In all FDM groups, there was a
myopic shift in refraction in the deprived eyes when compared
to the fellow eyes. The largest myopic shift was observed in
the FDM-only group (−4.06 D) and the vehicle-FDM group
(−3.28 D). APO treatment inhibited the myopic shift in the
deprived eyes compared to the fellow eyes (Figure 3A). In the
0.025 ng/µl APO-FDM group there was a shift of −3.20 D and
in the 0.25 ng/µl APO-FDM group the shift decreased to
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2828−1.86 D when compared to the fellow eyes (p≤0.013, paired
sample t-test). In the 2.5 ng/µl APO-FDM group, there was
no difference in refraction between the deprived eyes and the
fellow eyes (p=0.283, paired sample t-test), indicating that
APO at this dose abolished the effect of form deprivation. In
parallel  with  refractive  changes,  vitreous  length  of  the
deprived eyes increased significantly from day 0 to day 11
with a mean increase of 0.12 mm in the FDM-only group and
0.11 mm in the vehicle-FDM group (Figure 3B). Local APO
treatment  also  slowed  down  vitreous  lengthening  of  the
deprived eyes in a concentration-dependent manner in the
0.25 ng/µl and 2.5 ng/µl APO-FDM groups since there was
no difference between the deprived eyes and fellow eyes in
these 2 groups (p≥0.170, paired sample t-test).
The  corneal  radius  of  curvature  and  lens  thickness
increased significantly from day 0 to day 11 in both eyes of
Figure 1. Retinal DA and DOPAC levels
and  the  DOPAC/DA  ratio  in  normal
control,  FDM-only  and  defocus-only
groups. DA and DOPAC concentrations
were determined in retinal extracts at
day  11  of  treatment  (FDM:  deprived
eyes; FDM fel: fellow eyes to deprived
eyes; defocus: defocused eyes; defocus
fel: fellow eyes to defocused eyes). The
levels of retinal DA, DOPAC, and the
DOPAC/DA  ratio  were  significantly
lower in the deprived eyes compared to
their  fellow  eyes  (*  p<0.05,  paired
sample  t-test).  The  levels  of  DA  and
DOPAC  in  the  deprived  eyes  were
significantly lower than in the normal
control  eyes  (*p<0.05,  one-way
ANOVA). In contrast, the defocus-only
group showed similar levels of DA and
its  metabolites  between  eyes  of  the
individual  animals  (p>0.05,  one-way
ANOVA). However, the defocused eyes
showed a significant reduction in retinal
DOPAC  level  but  no  significant
changes in DA or DOPAC/DA levels
when compared to the normal control
eyes (*p<0.05, one-way ANOVA).
Figure 2. Time course of changes in total
amount of APO in the vitreous chamber
after subconjunctival injection of APO.
The  amount  of  APO  in  the  vitreous
chamber  peaked  0.5  h  or  less  after
injection  and  decreased  rapidly,
reaching  a  plateau  at  12  h  and
maintaining plateau levels at 24 h. The
data at each time point was from cross-
section measurements.
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2829individual animals in all the FDM groups (p<0.05: day 0
versus day 11 for all groups, independent t-test), except the
cornea radius of curvature in the 250 ng APO-FDM group
(p=0.079: day 0 versus day 11, independent t-test). There was
no significant difference between the deprived and fellow
eyes for these two parameters at any time point (p≥0.271 for
corneal radius of curvature; p≥0.12 for lens thickness, paired
sample t-test).
Defocus groups: In all defocus-induced myopia groups, there
were no significant differences in biometric results between
the fellow eyes of all defocus groups and the right eyes of the
normal control group at day 11 (p≥0.070: right eyes in normal
control versus fellow eyes in each defocus group, one-way
ANOVA).  The  defocused  eyes  in  all  defocus  groups
developed  significant  myopia  at  day  11  compared  to  the
fellow eyes (p≤0.001, paired sample t-test). Consistent with
the refractive changes, the vitreous length of the defocused
Figure  3.  Biometric  measurements  in
FDM,  vehicle-FDM,  and  APO-FDM
(0.025 to 250 ng/μl) groups before and
at 11 days of FDM. A: Refraction; B:
Vitreous length; C: Axial length. APO
effectively blocked the development of
FDM  by  inhibiting  the  excessive
elongation  of  vitreous  chamber  in  a
dose-dependent  pattern  (*  indicates  a
p<0.05  compared  to  the  fellow  eye,
paired t-test).
Molecular Vision 2011; 17:2824-2834 <http://www.molvis.org/molvis/v17/a307> © 2011 Molecular Vision
2830eyes increased significantly from day 0 to day 11 in all the
groups compared to the fellow eyes (p≤0.006, paired sample
t-test).  Corneal  radius  of  curvature  and  lens  thickness
increased significantly over the 11-day in all defocus groups
(p≤0.004: day 0 versus day 11, independent t-test). There was
no significant difference of all the parameters between eyes
of  individual  animals  at  any  time  point  (p≥0.165,  paired
sample t-test) in all the groups.
DISCUSSION
This present study shows that degree of myopic shift with the
associated increase in vitreous length is similar between FDM
and defocus-induced myopia. However, the level of DA and
DOPAC is lower in the deprived eyes but remains unchanged
in the defocused eyes when compared to the fellow and normal
control eyes, though a larger sample for defocus groups is
needed  to  confirm  the  insignificant  change  in  DA.  These
changes in DA synthesis and metabolism are consistent with
previous  studies  on  FDM  [41,48]  and  defocus-induced
myopia [41,48] in chickens, indicating that the dopaminergic
system is involved in the development of FDM more actively
than in the development of defocus-induced myopia. Given
that the less involvement of the dopaminergic system in the
defocus-induced  myopia  but  similar  biometric  outcomes
between the 2 models, another neurologic mechanism, such
as the cholinergic system, may act as a “back-up” for the
development of defocus-induced myopia to compensate the
insufficient involvement of the dopaminergic system. This
hypothesis  is  supported  by  an  inhibitory  effect  of  the
combination of atropine and APO on defocus-induced myopia
in chickens [16].
The dose-dependent inhibition of FDM by local APO
injection is in agreement with previous findings that local
injection  of  APO  inhibits  FDM  in  chickens  and  primates
[27,28,42,62]. For example, subconjunctival injection of APO
at 2.5 ng or intravitreal injection of APO at 5 pg to neonatal
chickens (younger than 20 days) can reduce 50% of the FDM
[27,42,63],  while  an  increased  dose  to  250  ng  APO  can
completely inhibit the FDM. The dosage curve of vitreous
APO presented in this study indicates that the amount of APO
was reduced significantly (by 4 orders) after the drug diffuses
across the guinea pig sclera. The concentration range used in
the experimental groups of this study (0.025 to 2.5 ng/µl) is 5
times lower than in chickens (0.125 to 12.5 ng/µl [42], ). Based
Figure  4.  Biometric  measurements  in
defocus-only,  vehicle-defocus,  and
APO-defocus  (0.025  to  250  ng/μl)
groups  before  and  at  11  days  of
hyperopic  defocus.  A:  Refraction;  B:
Vitreous length; C: Axial length. At the
concentrations examined, APO has no
statistically  significant  effect  on  the
development  of  defocus-induced
myopia.
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2831on the dosage curve in this present study, subconjunctival
injection  of  250  ng  APO  produces  a  higher  vitreous
concentration than the E50 dosage (50% effective) used in the
chickens (0.70–0.87 nM in guinea pig versus 0.056 nM in
chicken [42] probably due to a more permeable mammalian
sclera (not partially cartilage tissue as chicken sclera). The
decrease  in  retinal  DA  biosynthesis  in  FDM  supports  a
hypothesis that retinal DA regulates normal axial growth of
the  eye  and  a  relatively  hypodopaminergic  state  may
contribute to the development of axial myopia [31,47]. It is
noted that APO does not change the axial growth of the eye
under normal visual environment. The different effects of DA
agonist on eyes under FDM and normal visual development
could be due to a higher affinity for exogenous DA in the
deprived eyes compared to eyes exposed to a normal light
cycle [44,64].
In contrast to FDM, APO does not significantly inhibit
defocus-induced myopia even at a dose of 3 orders higher,
probably due to a lower sensitivity of the defocused eyes to
APO as the concentration of DA in these eyes is not reduced
(compared to the fellow eyes), resulting in more saturated DA
receptors in defocused-eyes. However, previous studies on
chickens  have  shown  that  APO  and  2-amino-6,7-
dihydroxy-1,2,3,4-tetrahydronaphthanele  hydrobromide
(ADTN:  another  DA  agonist)  can  significantly  inhibit
defocus-induced myopia in chickens [11,16]. It is noted that
the negative power of the lenses used in these previous studies
are much higher than −4.00 D and the animals used were much
younger than those used in the present study (−15 D lens on
8 day old chickens) [16,27,42]. Therefore, the discrepancy in
results of defocus-induced myopia between the present and
previous  studies  may  be  due  to  differences  in  age  of  the
animals (the younger the animals, the more susceptible to
myopic  development),  compensation  amplitude  of  the
defocused eye and animal species used for experiments. More
recent studies show that spiperone (D2 antagonist) completely
inhibits the protective effect of temporal re-exposure of the
deprived eye against FDM [62,65], but can partially inhibit
defocus-induced myopia [62,65]. These results suggest an
opposite  role  of  dopamine  agonists  between  FDM  and
defocus-induced  myopia  but  again  indicate  that  the
involvement of doparminergic system is higher in FDM than
in defocus-induced myopia.
Retinal DA release is sensitive to light exposure [38,64]
and  involved  in  visual  stimulated  signaling.  The  light
transmittance and visual input in deprived eyes are weaker
than in defocused eyes. This may explain the difference in
retinal DA level observed in these two models (Figure 1). This
notion is supported by previous findings as bright luminance
and flickering can increase DA release and block FDM in
chickens  but  only  slows  down  or  partially  inhibits  the
development of defocus-induced myopia [7,18,40,46]. Form
deprivation may obscure the dark-light cycle and therefore
disrupts the circadian rhythm of ocular growth [41]. Restoring
this circadian rhythm has been shown to inhibit FDM but not
defocus-induced  myopia  [46].  In  this  present  study,  local
injection of APO at 9:00 AM mimics the cycle of increased
DA release that usually occurs during daytime and may help
maintain the normal circadian rhythm of DA in the deprived
eye. This could explain why local administration of APO can
inhibit FDM but not defocus-induced myopia.
In  summary,  subconjuctival  injection  of  APO  can
produce an effective concentration of intravitreous APO to
attenuate myopic shift and axial elongation following form
deprivation. However this inhibitory effect is less effective in
defocus-induced  myopia.  Thus,  DA  signal  appears  to  be
critical in development of FDM but not necessarily involved
in  defocus-induced  myopia,  indicating  that  different
neurochemical mechanisms may be involved in dopamine-
mediated axial growth for these two visual manipulations.
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